Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 9/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BRD1 | O95696 | 1/20 | 0.34 |
| ▸ | TAF1 | P21675 | 1/20 | 0.34 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23516287 | 0.96 | PGR (0.37) | BRD4CASP3PGRBRD1TAF1 | |
| SCHEMBL19848961 | 0.93 | BRD4 (0.42) | BRD4CASP3PGRMEN1USP2 | |
| SCHEMBL19848966 | 0.92 | BRD4 (0.41) | BRD4CASP3PGRMEN1USP2 | |
| SCHEMBL23515898 | 0.91 | PGR (0.39) | BRD4CASP3PGRMEN1USP2 | |
| SCHEMBL23515905 | 0.89 | CHEK1 (0.39) | BRD4CASP3PGRMEN1USP2 | |
| SCHEMBL23515897 | 0.89 | PGR (0.39) | BRD4CASP3PGRCHEK1 | |
| SCHEMBL23516312 | 0.88 | BRD4 (0.38) | BRD4CASP3PGRCHEK1 | |
| SCHEMBL19848947 | 0.87 | CASP3 (0.47) | BRD4CASP3PGRMEN1USP2 | |
| SCHEMBL23516118 | 0.85 | CASP3 (0.39) | BRD4CASP3BRD1TAF1BRPF1 | |
| SCHEMBL23515910 | 0.84 | BRD4 (0.42) | BRD4CASP3PGRTGFBR1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11276825-B2 | Organic molecules for use in organic devices | CYNORA GMBH (DE) | 2022-03-15 | — | — | US | disclosed |
| US-20210184134-A1 | ORGANIC MOLECULES FOR USE IN ORGANIC DEVICES | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210184134-A1 | ORGANIC MOLECULES FOR USE IN ORGANIC DEVICES | CHRM1, C1S, DNMT3L | BRD4 1051/4885CASP3 2113/4885PGR 1964/4885 |
| US-11276825-B2 | Organic molecules for use in organic devices | AOX1, OR10J3, L1CAM | BRD4 3545/4885CASP3 2340/4885PGR 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.